Recently, Ogitani et al. reported that a HER2-targeting ADC termed DS-8201a was successfully conjugated with 8 molecules of novel topoisomerase I inhibitors per antibody, and that this ADC exhibited potent anti-tumor activities in a wide range of HER2-positive animal models with favorable pharmacokinetics and safety profiles [82]. Here, ERBB2 is linked to neoplasm.